Vorasidenib for Certain IDH-Mutant Gliomas: Is It Worth It?
Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a “breakthrough,” whereas others call the approval “premature.”
Medscape Medical News
source https://www.medscape.com/viewarticle/vorasidenib-certain-idh-mutant-gliomas-it-worth-it-2024a1000lvu?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/vorasidenib-certain-idh-mutant-gliomas-it-worth-it-2024a1000lvu?src=rss
Comments
Post a Comment